# Ribociclib (LEE011) Rollover Study for Continued Access

Source: https://onco.cc/trials/nct02934568/  
OnCo record `nct02934568` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of LEE011 in advanced solid tumours, run by Novartis Pharmaceuticals, active and no longer recruiting.

## Summary

Ribociclib (LEE011) Rollover Study for Continued Access is a phase 2 interventional study registered as NCT02934568 by Novartis Pharmaceuticals, with 22 participants enrolled, started 2016-12-15 and due to reach its primary completion in 2027-02-01. Interventions recorded: LEE011.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02934568
- Phase: 2
- Setting: An Open-label, Multi-center Rollover Protocol for Patients Who Have Participated in a Novartis-sponsored Ribociclib (LEE011) Study and Are Continuing to Benefit From Ribociclib as Single Agent or in Combination With Other Investigational Treatments
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 22

## Sources

- ClinicalTrials.gov NCT02934568: https://clinicaltrials.gov/study/NCT02934568

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Advanced Accelerator Applications (Novartis)](https://onco.cc/companies/advanced-accelerator-applications/)

---
JSON: https://onco.cc/api/v1/entities/nct02934568.json